Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions

On March 12, 2019, the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:

### Therapeutic Class Reviews

- ACEI & ACEI Combination
- ARB & ARB Combination
- Statin & Statin Combination
- Phosphodiesterase 5 Inhibitor
- Beta Blockers
- Calcium Channel Blockers
- Cholinesterase Inhibitor
- Cystic Fibrosis Agents
- Ophthalmic Antihistamines
- PCSK9 Inhibitors
- Pulmonary Arterial Hypertension
- Leukotriene Receptor Antagonist
- Anticholinergic
- ESAs
- ICS/LABA Combination
- Short acting Beta Agonists
- Muscle Relaxants
- Second Generation Antihistamines

### Drug Monographs

- None

### Prior Authorization Criteria Updates

New criteria was created for the following agents: None

Updates were made to the criteria for the following agents:

- Nicardipine, Nicardipine CR
- Epinastine (Elestat)
- Emedastine (Emadine), Nedocromil (Alocril), Olopatadine (Pazeo)
- Zileuton (Zyflo)
- Scopolamine patch (Trasderm-Scop)
- Dronedarone (Multaq)
- Clonidine ER (Kapvay)
- Omalizumab (Xolair)
- Evolocumab (Repatha)
- Entecavir (Baraclude)

Updates were made to the criteria for the following classes:

- ACEI & ACEI Combination
- ARB & ARB Combination
- Statin & Statin Combination
- Beta Blockers
- Calcium Channel Blockers
- Cystic Fibrosis Agents
- Ophthalmic Antihistamines
- PCSK9 Inhibitors
- Leukotriene Receptor Antagonist
- Anticholinergic
- ESAs
- ICS/LABA Combination
- Short acting Beta Agonists
- Muscle Relaxants
- Second Generation Antihistamines

Criteria reviewed and unchanged:
- PDE 5 Inhibitors
- Cholinesterase Inhibitor
- IV Iron
- Pulmonary Arterial Hypertension Agents
- Alprostadil (Caverject, Muse)
- Roflumilast (Daliresp)
- Clobazam (Onfi)
- Dabigatran (Pradaxa)
- Pregabalin (Lyrica)

The following drugs were added to the CCHP formulary:
- Zyban (Bupropion SR)
- Adalat CC (nifedipine ER)
- Protopic (tacrolimus) ointment

**Guest Speaker(s)**
- None

**CCHP P&T Committee approved the following modifications to the formulary:**

<table>
<thead>
<tr>
<th>Medication Name &amp; Dosage Strength</th>
<th>Approved Formulary Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bupropion SR 150mg tabs (Zyban)</td>
<td>Added to the formulary with tier 1 status.</td>
</tr>
<tr>
<td>Nifedipine ER (Adalat CC) 30, 60, 90mg tablets</td>
<td>Added to the formulary with tier 1 status</td>
</tr>
<tr>
<td>Tacrolimus 0.03% ointment, 0.1% ointment (Protopic)</td>
<td>Added to the formulary with tier 2 status (QL 30g)</td>
</tr>
<tr>
<td>Entecavir</td>
<td>Tablet splitting is no longer a requirement for the 0.5mg dose</td>
</tr>
</tbody>
</table>

**New Product Reviews**